Director's Share Dealing

RNS Number : 4211I
Hutchison China Meditech Limited
21 March 2018
 

 

 

Director's Share Dealing

 

London: Wednesday, March 21, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on March 16, 2018 at a price of US$33.86 per ADS.

 

Following the above purchase, the spouse of Mr Jack is interested in 3,000 ADSs, representing approximately 0.002% of the current issued share capital of Chi-Med.

 

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation. 

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

 

Name

 

Ms Debbie Sue Chung

 

2

Reason for the notification

 

a)

 

Position/status

 

Spouse of Mr Graeme Jack, an Independent Non-executive Director of Chi-Med

 

 

b)

 

Initial notification/Amendment

 

 

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hutchison China MediTech Limited

 

b)

 

 

LEI

 

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

 

 

ADS each representing one half of one Ordinary Share of US$1.00

 

ADS ISIN: US44842L1035

 

 

b)

 

Nature of the transaction

 

 

Acquisition of 3,000 ADSs on March 16, 2018 at a price of US$33.86 per ADS

 

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

US$33.86

3,000

 

 

 

d)

 

Aggregated information

 

-

Aggregated volume

-

Price

 

 

           

N/A

 

e)

 

Date of the transaction

 

2018-03-16

 

 

f)

 

Place of the transaction

 

Nasdaq Stock Market

 

 

 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit: www.chi-med.com.

 

CONTACTS

Investor Enquiries



Mark Lee, Senior Vice President, Corporate

Finance & Development

+852 2121 8200





U.K. & International Media Enquiries



Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk




U.S. Based Media Enquiries



Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com




Investor Relations



Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

David Dible, Citigate Dewe Rogerson  

+44 7967 566 919 (Mobile)

david.dible@citigatedewerogerson.com




Panmure Gordon (UK) Limited



Richard Gray / Andrew Potts

+44 (20) 7886 2500


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLIFLAVEILFIT
UK 100